All News
ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Read Article
Metformin Lowers Gout Risk in Pre-Diabetes
A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout.
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Metformin Lowers Gout Risk in Pre-Diabetes
A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout.
https://t.co/IQ1Z7rhhp1 https://t.co/vYKBKsWh0y
Dr. John Cush RheumNow ( View Tweet)
CBD Products Disappointing for Pain
There is no evidence that CBD products reduce chronic pain, and taking them is a waste of money and potentially harmful to health, according to new research led by the University of Bath in the UK.
https://t.co/0NOGOTkpke
Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance Grants for Lupus Innovation
The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
https://t.co/nAlpFyiyUO https://t.co/Rj2JzmmhHO https://t.co/8IG9EkyMad
Dr. John Cush RheumNow ( View Tweet)
Gangsin: 갱신 Korean: refresh, renew, updated
Over the last 20+ years, I have listened to patients confide their personal stories. Some remained paralyzed in their current state of distress, --I was one of them
https://t.co/92tu3de4Ja https://t.co/ePGshN9t51 https://t.co/shdaov1ZPf
Dr. John Cush RheumNow ( View Tweet)
JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits
- Dx algorithm
- Pathophys
- Rx options
- Alternative Rx
https://t.co/epiP8Yi1Oz https://t.co/GsORbADJZy https://t.co/K7Q6Yrx1yI
Dr. John Cush RheumNow ( View Tweet)
Hypertension not associated with High NSAID Doses in AxSpA
At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs.
https://t.co/4XLr01wwo1 https://t.co/hdBYec6wmd
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk
Links:
Dr. John Cush RheumNow ( View Tweet)
No Great Options for Treating VEXAS
For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ
Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Dr. John Cush RheumNow ( View Tweet)
ACR Website to Support PCPs
The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients.
https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt
Dr. John Cush RheumNow ( View Tweet)
Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/qWUwrAcCJZ https://t.co/6S7Y6p7BnF
Dr. John Cush RheumNow ( View Tweet)
Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18 vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o
Dr. John Cush RheumNow ( View Tweet)
Anakinra in COVID showed mixed (often negative) results. But this Turkish retrospective observational study comparing standard of care to IV anakinra in severe COVID pts. IV ANAK had less thromboembolic event (5% vs 12.3%, p = 0.038), better survival https://t.co/4webWJKEfB https://t.co/85GnCd6N8O
Dr. John Cush RheumNow ( View Tweet)
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g
Links:
Dr. John Cush RheumNow ( View Tweet)
There's a huge difference between knowing the name of something and knowing something.
We talk in fact-deficient, obfuscating generalities to cover up our lack of understanding.
Prof. Feynman ProfFeynman ( View Tweet)
#JuneIssue | Relapsing polychondritis is challenging to diagnosis owing to overlapping symptoms with other conditions
Learn more about the clinical features and differential diagnoses in this #Review
https://t.co/iXl9rQ0ONS
NatRevRheumatol NatRevRheumatol ( View Tweet)
Kaiser/California EHR study of #SLE pregnancies (2011-2020) - 657 pregnancies in 453 prs; The live birth rate = 74%, 23% w/ Spontaneous Ab, 2% ectopic/molar & <1% stillbirths. Variable outcomes by race & ethnicity, aPL status & nephritis history https://t.co/gvmYpTuFon https://t.co/9TeG8kfLmK
Dr. John Cush RheumNow ( View Tweet)